Bank of America’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,297,438
| Closed | -$61.6M | – | 7321 |
|
|
2025
Q3 | $61.6M | Sell |
1,297,438
-23,023
| -2% | -$1.11M | ﹤0.01% | 1556 |
|
|
2025
Q2 | $70.5M | Buy |
1,320,461
+1,059,860
| +407% | +$48.2M | 0.01% | 1423 |
|
|
2025
Q1 | $10.5M | Buy |
260,601
+194,337
| +293% | +$8.24M | ﹤0.01% | 3078 |
|
|
2024
Q4 | $1.84M | Sell |
66,264
-93,294
| -58% | -$2.83M | ﹤0.01% | 4521 |
|
|
2024
Q3 | $4.58M | Sell |
159,558
-102,672
| -39% | -$2.68M | ﹤0.01% | 3814 |
|
|
2024
Q2 | $6.15M | Sell |
262,230
-163,641
| -38% | -$3.5M | ﹤0.01% | 3432 |
|
|
2024
Q1 | $10.8M | Sell |
425,871
-63,770
| -13% | -$1.53M | ﹤0.01% | 2920 |
|
|
2023
Q4 | $11.4M | Buy |
489,641
+294,756
| +151% | +$5.81M | ﹤0.01% | 2737 |
|
|
2023
Q3 | $9.86M | Buy |
194,885
+45,966
| +31% | +$2.14M | ﹤0.01% | 2725 |
|
|
2023
Q2 | $6.95M | Sell |
148,919
-82,502
| -36% | -$3.78M | ﹤0.01% | 3068 |
|
|
2023
Q1 | $8.85M | Buy |
231,421
+29,032
| +14% | +$1.29M | ﹤0.01% | 2949 |
|
|
2022
Q4 | $11.1M | Buy |
202,389
+132,069
| +188% | +$5.66M | ﹤0.01% | 2594 |
|
|
2022
Q3 | $2.39M | Buy |
70,320
+31,842
| +83% | +$487K | ﹤0.01% | 4098 |
|
|
2022
Q2 | $363K | Sell |
38,478
-23,763
| -38% | -$248K | ﹤0.01% | 5656 |
|
|
2022
Q1 | $883K | Buy |
62,241
+22,452
| +56% | +$393K | ﹤0.01% | 5385 |
|
|
2021
Q4 | $842K | Sell |
39,789
-14,260
| -26% | -$316K | ﹤0.01% | 5444 |
|
|
2021
Q3 | $1.21M | Buy |
54,049
+45,299
| +518% | +$1.03M | ﹤0.01% | 4897 |
|
|
2021
Q2 | $217K | Sell |
8,750
-1,888
| -18% | -$53K | ﹤0.01% | 6039 |
|
|
2021
Q1 | $308K | Buy |
10,638
+3,106
| +41% | +$94K | ﹤0.01% | 5730 |
|
|
2020
Q4 | $194K | Sell |
7,532
-24,664
| -77% | -$686K | ﹤0.01% | 5614 |
|
|
2020
Q3 | $991K | Buy |
32,196
+23,321
| +263% | +$815K | ﹤0.01% | 4214 |
|
|
2020
Q2 | $221K | Buy |
8,875
+6,126
| +223% | +$140K | ﹤0.01% | 5171 |
|
|
2020
Q1 | $58K | Sell |
2,749
-3,209
| -54% | -$68.8K | ﹤0.01% | 5801 |
|
|
2019
Q4 | $132K | Buy |
5,958
+3,997
| +204% | +$82.7K | ﹤0.01% | 5858 |
|
|
2019
Q3 | $46K | Buy |
+1,961
| New | +$45.6K | ﹤0.01% | 6344 |
|
Other funds holding AKRO
Bank of America's AKRO Position: Q4 2025 in Review
Bank of America sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,297,438 shares — an estimated $61.6M sold.
Bank of America first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $70.5M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Bank of America reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Bank of America sold 1,297,438 Akero Therapeutics shares in Q4 2025, an estimated $61.6M.
- Bank of America first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Bank of America's Akero Therapeutics position peaked at $70.5M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.